Specifically, our aims were to determine whether the infective disease process and routine management with anti‐TB medicines affect these biomarkers in the absence of DILI and to characterise how miR‐122 and K18 change in relation to ALT and in cases of DILI. The gene discussed is KRT18; the disease is tuberculosis.